Enveric Biosciences
ENVB
11 hedge funds and large institutions have $382K invested in Enveric Biosciences in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
22% more funds holding
Funds holding: 9 → 11 (+2)
7% more capital invested
Capital invested by funds: $357K → $382K (+$25.6K)
0.01% more ownership
Funds ownership: 0.05% → 0.06% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$62.7K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29K |
| 3 |
VF
Virtu Financial
New York
|
+$24.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.68K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.47K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $240K | +$62.7K | +149 | +23% |
|
2
BlackRock
New York
| $49.2K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $24K | +$9.68K | +23 | +42% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $21K | +$29K | +69 | New |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $20.2K | -$5.47K | -13 | -16% |
|
|
VF
6
Virtu Financial
New York
| $18K | +$24.8K | +59 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $8.85K | +$7.15K | +17 | +131% |
|
8
Group One Trading
Chicago,
Illinois
| $459 | – | – | – |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $249 | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $166 | – | – | – |
|
11
Wells Fargo
San Francisco,
California
| $49 | – | – | – |
|
12
Morgan Stanley
New York
| $2 | – | – | – |
|
|
CS
13
Credit Suisse
Zurich,
Switzerland
| – | -$2 | – | – |
|
ENVB Hedge Fund Activity: Q1 2023 in Review
11 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q1 2023, worth a combined $382K — up 7.2% from $357K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ENVB positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $62.7K. The largest seller was Vanguard Group, cutting an estimated $5.47K.
- 11 institutional investors held Enveric Biosciences (ENVB) as of Q1 2023, up from 9 in Q4 2022.
- Funds reported $382K of Enveric Biosciences stock for Q1 2023, up 7.2% quarter-over-quarter.
- 2 funds opened new Enveric Biosciences positions in Q1 2023 and 0 closed out, a net change of +2 holders.
- The largest Enveric Biosciences buyer in Q1 2023 was AdvisorShares Investments, an estimated $62.7K added.
- The largest Enveric Biosciences seller in Q1 2023 was Vanguard Group, an estimated $5.47K sold.
Based on aggregated 13F filings for Q1 2023.